

# **Lions Eye Institute Limited**

**ACN 106 521 439**

**General Purpose Financial Statements**

**For the Year Ended 31 December 2025**

# Lions Eye Institute Limited

31 December 2025

## Contents

	<b>Page</b>
Directors' report	4
Consolidated statement of profit or loss and other comprehensive income	8
Consolidated statement of financial position	9
Consolidated statement of changes in equity	10
Consolidated statement of cash flows	11
Notes to the consolidated financial statements	12
Directors' declaration	29
Independent auditor's report	30
Auditor's independence declaration	33

# Lions Eye Institute Limited

ACN 106 521 439

31 December 2025

## Director's Report

The directors present their report together with the financial report of Lions Eye Institute Limited ("Company" or "LEI") and its controlled entity (collectively, the "Group") for the financial year ended 31 December 2025 and the auditor's report thereon.

### i. Directors

The names of the directors in office at any time during or since the end of the year are:

- Anthony Joyner (Chair)
- Glen Power (Managing Director)
- Jane den Hollander (Deputy Chair)
- Grant Waterer (resigned June 2025)
- Amanda Williams
- Angus Turner (resigned September 2025)
- Antony Clark
- Professor Andrew Turpin (commenced May 2025)
- Professor Chandra Balaratnasingam (commenced August 2025)

The directors have been in office since the start of the financial year to the date of this report, unless otherwise stated.

#### **Anthony (Tony) Joyner, B. Juris (Hons), LLB – Chair**

Tony Joyner joined the Board of the Lions Eye Institute Limited in 2013 and was elected its chair in 2023. He has more than 35 years' experience as a commercial and corporate lawyer, and for nine years was the Managing Partner of the Perth office of international law firm Herbert Smith Freehills. He sat on the global board of the firm for nine years and chaired its Risk Management and Audit Committee. He is also a board member of the WA Chamber of Commerce and Industry

#### **Glen William Power B.Sc (Hons), DPhil (Oxon)**

Dr Glen Power joined the Board in May 2024 when he assumed the Managing Director role, having held the role of Chief Executive Officer at LEI since 2021. Dr Power has spent the past 28 years in senior executive roles in both the public and private health sectors, including 19 years as a chief executive officer or general manager of several hospitals around Australia. He served for three years as chief of staff and principal policy advisor to the Minister for Health in Western Australia. Glen is a Rhodes Scholar and holds a doctoral degree in metabolic biochemistry from Oxford University. He also studied undergraduate science and law at Melbourne, Murdoch and the University of Western Australia. Glen has served on the boards of several medical research institutes and educational charities and is currently the Western Australian director on the board of the Rhodes Scholarships in Australia Pty Ltd and a director of aged care provider Bethanie Group Incorporated and a director of Ninox Vision Pty Ltd.

#### **Jane den Hollander AO, Hon Doc; Hon Doc; PhD; SC Hons**

Professor Emeritus Jane den Hollander AO joined the Board of the Lions Eye Institute in 2020. She received an Order of Australia for her distinguished service to tertiary education in the 2017 Australia Day Honours. She is currently a Director of the WA Public Health Authority (WAPHA) Board and Senator on the Board of The University of Western Australia. She is also Chair of the Centre for Stories Board, a Director of Navitas and a Director of the Breakthrough Victoria Pty Ltd Board.

## **Lions Eye Institute Limited**

**ACN 106 521 439**

**31 December 2025**

### **Director's Report**

**Grant Waterer, MBBS, FRACP, FCCP, PhD, MBA, resigned June 2025**

Professor Grant Waterer joined the Board of LEI in 2018 and resigned in June 2025. He is a Fellow of the Royal Australasian College of Physicians and the American College of Chest Physicians. He is Professor of Medicine at UWA and Executive Director of Medical Services, East Metropolitan Health Service. He holds a PhD focused on pneumonia and a Master of Business Administration.

**Amanda Williams BCom, CAANZ**

Amanda Williams joined the board in June 2023. She is a partner at PwC Private in Assurance with over 26 years of auditing experience, including 15 years as a partner. She is a specialist in auditing not-for-profit entities, however during her tenure at PwC her portfolio includes both not-for-profit to multinational companies and foreign owned entities. She holds a Bachelor of Commerce from the University of Western Australia and is a Registered Company Auditor in Australia and New Zealand. Amanda has previously served as a Board member and Treasurer for an independent girls' school in Perth.

**Angus Turner MBBS (Hons) MSc (Oxon), FRANZCO, resigned September 2025**

Professor Angus Turner resigned from the board in September 2025. As the founding Director of Lions Outback Vision, he was actively involved in the delivery of specialist outreach services to remote and Indigenous communities, building a rigorous evidence base to guide the development of sustainable eye health care.

Professor Turner is the Director for UWA's Centre for Ophthalmology and Visual Science, serves as a clinical lecturer for the Rural Clinical School at UWA, Notre Dame University and Curtin University and sits on various advocacy committees and forums, including the Board of the Royal Flying Doctor Service Western Operations.

**Antony Clark MBBS, PhD, FRANZCO**

Dr Antony Clark is a consultant ophthalmologist at the Lions Eye Institute, Sir Charles Gairdner and Perth Children's Hospitals with interests in glaucoma and paediatric ophthalmology. Dr Clark has a PhD in public health and has maintained a research focus on paediatric ophthalmology, including in childhood myopia where he led the WA ATOM (Atropine for the Treatment of Myopia) Study into childhood myopia with Professor David Mackey. He is a senior research fellow with the Centre for Ophthalmology and Visual Science, UWA.

**Andrew Turpin, commenced May 2025**

Professor Andrew Turpin joined the board of the Lions Eye Institute in 2025 and joined both the Lions Eye Institute and Lions Curtin Chair of Ophthalmic Data in 2023. Prior to this, he was acting executive director of the research translation hub, Melbourne Connect, during its formation and lead academic on the Petascale Campus Initiative, which built large computational infrastructure to support all research at the University of Melbourne. He was the founding director of the Melbourne Data Analytics Platform. He holds a PhD in computer science and has published over 200 research papers in both computer and vision science. Prior to his academic roles, he worked in life insurance as an assistant actuary.

**Chandra Balaratnasingam, commenced August 2025**

Professor Chandra Balaratnasingam is a Clinical Professor of Ophthalmology at The University of Western Australia and consultant vitreoretinal surgeon at LEI and Sir Charles Gairdner Hospital. He has been a part of LEI for over 25 years, initially joining the organisation as a medical student where he completed research projects with the Physiology and Pharmacology group. Chandra completed his PhD at LEI and commenced clinical practice in 2016. He is the director of the Perron Paediatric Retinopathy Initiative and leads a talented team of clinicians and scientists at LEI to develop new strategies to prevent diabetes-related blindness.

# Lions Eye Institute Limited

ACN 106 521 439

31 December 2025

## Director's Report

### ii Meetings of Directors

	Held	Attended
G Power	6	6
A Joyner	6	6
A Turpin	4	4
C Balaratnasingam	3	3
G Waterer	3	2
J D Hollander	6	5
A Williams	6	6
A Turner	5	5
A Clark	6	5

### ii. Review of operations

The Group's operations for the financial year resulted in a surplus of \$342,927 (2024: \$8,253,641)

During the year, the Group's wholly owned subsidiary, Aecona Pty Ltd, was wound down and subsequently deregistered.

In addition, the Group made a new investment in Ninox Pty Ltd during the year. This investment has been recognised in accordance with the Group's accounting policies as an investment in an associate.

### iii. Principal activities

The Group's purpose is to prevent and cure blindness and eye disease. It aspires to better vision for all.

It seeks to achieve leadership in scientific research and clinical practice in the prevention of blindness and eye disease through:

- global leadership in scientific research
- translation of research into community outcomes
- a commitment to growing the reach of our research capabilities and clinical services
- development and training of outstanding eye care professionals and researchers
- community engagement and education to build awareness, maintain a high reputation and increase funding

by:

- delivering excellent eye care
- conducting ongoing research, collaborating and pursuing national and international scientific linkages with other world class research and clinical groups to prevent blindness
- integrating and expanding clinical services and research activities, including in remote and regional areas
- teaching and training new ophthalmologists through the University of Western Australia and other international bodies
- providing strategic advice to state, national and international bodies on the prevention of blindness.

### iv. Company information

The Company is incorporated under the *Corporations Act 2001* and is a public company limited by guarantee. If the

# Lions Eye Institute Limited

ACN 106 521 439

31 December 2025

## Director's Report

Company is wound up, each member is required to contribute a maximum of \$10 each towards meeting any outstanding obligations of the Company. As of 31 December 2025, the collective liability of members was \$500 (2024: \$490).

The Company's constitution does not permit dividends to be paid and thus no dividends were paid or are recommended to be paid.

### v. Environmental regulations

The Group's operations are not regulated by any significant environmental regulation under a law of the Commonwealth or of a State or Territory.

### vi. Subsequent events

Subsequent to year end, an additional \$3 million of the corporate loan facility disclosed in Note 19 of the Financial Statement was drawn down on 3 February 2026.

On 15 January 2026, the Company made an additional investment of \$4,000,000 in Ninox.

No other matters or circumstances that have arisen since the end of the financial year that have significantly affected or may significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in future years.

### vii. Indemnification and insurance of directors and officers

#### Indemnification

The Company has agreed to indemnify the current directors and officers of the Company against all liabilities in defending proceedings against them that may arise from their position as directors and officers of the Company unless the liability arises out of conduct involving a lack of good faith.

#### Insurance premiums

The Company maintains insurance cover for directors and officers. During the year, the cost of premiums for this insurance was \$10,785 (2024: \$10,785).


### viii. Indemnification and insurance of auditors

To the extent permitted by law, the Company has agreed to indemnify its auditors, Ernst & Young Australia, as part of the terms of its audit engagement agreement against claims by third parties arising from the audit (for an unspecified amount). No payment has been made to indemnify Ernst & Young during the financial year.

### ix. Auditor's independence declaration

A copy of auditor's independence declaration as required by Subdivision 60-C of the *Australian Charities and Not-for-Profits Commission Act 2012* is set out on page 30.

Signed in accordance with the resolution of the Board of Directors.



.....  
Anthony Joyner  
Chair  
Dated: 15 May 2026



.....  
Glen Power  
Managing Director  
Dated: 15 May 2026

**Lions Eye Institute Limited**  
**ACN 106 521 439**

**Consolidated statement of profit or loss and other comprehensive income**  
**As at 31 December 2025**

		<b>2025</b>	<b>2024</b>
	<b>Note</b>	<b>\$</b>	<b>\$</b>
<b>Revenue and income</b>			
Revenue from ordinary activities	4	40,572,433	39,865,371
Other income	5	2,062,953	7,259,492
Net fair value gain on financial assets at fair value		764,704	3,627,959
Gain on loss of control of subsidiary		253,010	-
		<u>43,653,100</u>	<u>50,752,822</u>
<b>Expenses</b>			
Community initiatives	6	(7,364,798)	(8,083,007)
Corporate services	7	(6,102,346)	(5,773,888)
Medical and scientific research	8	(8,652,772)	(8,504,196)
Clinical expenses	9	(21,110,495)	(20,138,090)
Share of loss of associate	14	(79,762)	-
		<u>(43,310,173)</u>	<u>(42,499,181)</u>
<b>Surplus for the year</b>		342,927	8,253,641
Other comprehensive income		-	-
<b>Total comprehensive surplus for the year</b>		<u>342,927</u>	<u>8,253,641</u>

*The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.*

**Lions Eye Institute Limited**  
**ACN 106 521 439**

**Consolidated statement of financial position**  
**As at 31 December 2025**

	<b>Note</b>	<b>2025</b>	<b>2024</b>
		<b>\$</b>	<b>\$</b>
<b>Assets</b>			
<b>Current assets</b>			
Cash and cash equivalents	10	6,854,080	11,638,975
Trade and other receivables	11	3,983,990	4,583,147
Inventories		59,017	62,650
Other financial assets		64,000	64,000
Other current assets	12	740,817	508,555
<b>Total current assets</b>		<u>11,701,904</u>	<u>16,857,327</u>
<b>Non-current assets</b>			
Financial assets at fair value through profit and loss	13	37,881,289	37,702,513
Investment in associate	14	920,238	-
Property, plant and equipment	15	25,059,121	19,399,866
Right-of-use assets	16	845,876	1,584,061
<b>Total non-current assets</b>		<u>64,706,524</u>	<u>58,686,440</u>
<b>Total assets</b>		<u>76,408,428</u>	<u>75,543,767</u>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Trade and other payables	17	8,502,891	9,298,888
Lease liabilities	16	605,056	591,668
Employee benefit provisions	18	2,943,531	3,054,012
<b>Total current liabilities</b>		<u>12,051,478</u>	<u>12,944,568</u>
<b>Non-current liabilities</b>			
Borrowings	19	2,007,184	-
Lease liabilities	16	356,786	1,174,748
Employee benefit provisions	18	1,053,310	827,708
<b>Total non-current liabilities</b>		<u>3,417,280</u>	<u>2,002,456</u>
<b>Total liabilities</b>		<u>15,468,758</u>	<u>14,947,024</u>
<b>Net assets</b>		<u>60,939,670</u>	<u>60,596,743</u>
<b>Equity</b>			
Retained surplus		60,939,670	60,596,743
<b>Total equity</b>		<u>60,939,670</u>	<u>60,596,743</u>

*The above consolidated statement of financial position should be read in conjunction with the accompanying notes.*

**Lions Eye Institute Limited**  
**ACN 106 521 439**

**Consolidated statement of changes in equity**  
**For the year ended 31 December 2025**

	<b>Retained surplus</b>	<b>Total</b>
	\$	\$
<b>Balance at 1 January 2025</b>	60,596,743	60,596,743
Surplus for the year	342,927	342,927
Total comprehensive surplus	342,927	342,927
<b>Balance at 31 December 2025</b>	<b>60,939,670</b>	<b>60,939,670</b>

	<b>Retained earnings</b>	<b>Total</b>
	\$	\$
<b>Balance at 1 January 2024</b>	52,343,102	52,343,102
Surplus for the year	8,253,641	8,253,641
Total comprehensive surplus	8,253,641	8,253,641
<b>Balance as at 31 December 2024</b>	<b>60,596,743</b>	<b>60,596,743</b>

*The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.*

**Lions Eye Institute Limited**  
**ACN 106 521 439**

**Consolidated statement of cash flows**  
**For the year ended 31 December 2025**

	<b>2025</b>	<b>2024</b>
<b>Note</b>	<b>\$</b>	<b>\$</b>
<b>Cash flows from operating activities</b>		
Receipts from customers, donors and grantors	41,789,301	48,161,635
Payments to suppliers and employees	(41,377,952)	(44,319,606)
<b>Net cash provided by operating activities</b>	<u>411,349</u>	<u>3,842,029</u>
<b>Cash flows from investing activities</b>		
Interest received	431,030	258,167
Dividends received	1,478,601	1,388,230
Proceeds from sale of investment securities	585,927	6,581,458
Acquisition of investment securities	-	(12,149)
Payments for property, plant and equipment	(7,989,565)	(2,505,045)
Payment for investment in associate	(1,000,000)	-
<b>Net cash (used in)/provided by investing activities</b>	<u>(6,494,007)</u>	<u>5,710,661</u>
<b>Cash flows from financing activities</b>		
Proceeds from corporate loan	2,000,000	-
Payment of lease interest	(80,278)	(111,061)
Repayment of lease liabilities	(621,959)	(569,294)
<b>Net cash provided by/(used in) financing activities</b>	<u>1,297,763</u>	<u>(680,355)</u>
<b>Net (decrease)/increase in cash and cash equivalents</b>	(4,784,895)	8,872,335
Cash and cash equivalents at beginning of year	11,638,975	2,766,640
<b>Cash and cash equivalents at end of year</b>	10 <u><u>6,854,080</u></u>	<u><u>11,638,975</u></u>

*The above consolidated statement of cash flows should be read in conjunction with the accompanying notes.*

# Lions Eye Institute Limited

## ACN 106 521 439

### Notes to the consolidated financial statements

#### For the year ended 31 December 2025

#### 1 Corporate information

Lions Eye Institute Limited is a not-for-profit company limited by guarantee incorporated on 1 October 2003 and domiciled in Australia. Its registered office and principal place of business is 2 Verdun Street, Nedlands WA 6009.

The consolidated financial statements of the Company as at, and for the year ended 31 December 2025, were authorised for issue in accordance with a resolution of the directors on 15 May 2026.

#### 2 Material Accounting Policy Information

##### 2.1 Basis of Preparation

###### Statement of compliance

The consolidated financial statements have been prepared in compliance with the requirements of the *Australian Charities and Not-for-Profits Commission Act 2012* and Australian Accounting Standards – Simplified Disclosures.

The consolidated financial statements have been prepared on a historical cost basis, unless disclosed otherwise. The accounting policies that have been adopted in the preparation of this report are appropriate to meet the needs of the members. The consolidated financial report is presented in Australian dollars, and all values are rounded to the nearest dollar (\$).

###### Going concern

The Group has prepared the financial statements on the basis that it will continue to operate as a going concern.

##### 2.2 Current versus non-current classification

The Group presents assets and liabilities in the consolidated statement of financial position based on current/non-current classification.

An asset is current when it is: i) expected to be realised or intended to be sold or consumed in the normal operating cycle, ii) held primarily for the purpose of trading, iii) expected to be realised within twelve months after the reporting period or iv) a cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. All other assets are classified as non-current.

A liability is current when i) it is expected to be settled in the normal operating cycle, ii) it is held primarily for the purpose of trading, iii) it is due to be settled within twelve months after the reporting period or iv) there is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period. The Group classifies all other liabilities as non-current.

# Lions Eye Institute Limited

## ACN 106 521 439

### Notes to the consolidated financial statements

#### For the year ended 31 December 2025

## 2 Material Accounting Policy Information (continued)

### 2.3 Income tax

The Company is a charitable and/or public benevolent institution as described under Section 50-5 of the *Income Tax Assessment Act 1997* and is therefore exempt from income tax.

### 2.4 Goods and Services Tax (GST)

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office. In these circumstances the GST is recognised as part of the cost of acquisition of the asset or as part of an item of expense. Receivables and payables in the consolidated statement of financial position are shown inclusive of GST. Cash flows are presented in the consolidated statement of cash flows on a gross basis, except for the GST components of investing and financing activities, which are disclosed as operating cash flows.

### 2.5 Research and development costs

Research costs are expensed as incurred. Development expenditure on an individual project is recognised as an intangible asset when the Group can demonstrate:

- The technical feasibility of completing the intangible asset so that the asset will be available for use or sale
- Its intention to complete and its ability and intention to use or sell the asset
- How the asset will generate future economic benefits
- The availability of resources to complete the asset
- The ability to measure reliably the expenditure during development.

Following initial recognition of development expenditure as an asset, the asset is carried at cost less any accumulated amortisation and accumulated impairment losses. Amortisation of the asset begins when development is complete, and the asset is available for use. It is amortised over the period of expected future benefit. Amortisation is recorded in the profit or loss. During the period of development, the asset is tested for impairment at least annually.

### 2.6 Financial liabilities

Financial liabilities are recognised initially at fair value net of transaction costs and are subsequently measured at amortised cost using the effective interest method. Interest expense is recognised in profit or loss over the term of the instrument.

The Entity derecognises a financial liability when the obligation specified in the contract is discharged, cancelled or expires.

### 2.7 Changes in accounting policies and disclosures

The new and amended Australian Accounting Standards and Interpretations that apply for the first time in 2025 did not have a significant impact on the Group's financial statements. The Group has not early adopted any standards, interpretations or amendments that have been issued but are not yet effective. The Group intends to adopt the new or amended standards or interpretations when they become effective.

### 2.8 Basis of consolidation

The consolidated financial statements comprise the financial statements of the Company and its subsidiary. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee.

**Lions Eye Institute Limited**  
**ACN 106 521 439**

**Notes to the consolidated financial statements**  
**For the year ended 31 December 2025**

**2 Material Accounting Policy Information (continued)**

Specifically, the Group controls an investee if, and only if, the Group has:

- ▶ Power over the investee (i.e., existing rights that give it the current ability to direct the relevant activities of the investee)
- ▶ Exposure, or rights, to variable returns from its involvement with the investee
- ▶ The ability to use its power over the investee to affect its returns.

Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated financial statements from the date the Group gains control until the date the Group ceases to control the subsidiary. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

If the Group loses control over a subsidiary, it derecognises the related assets and liabilities, while any resultant gain or loss is recognised in profit or loss.

During the year, the Group’s wholly owned subsidiary, Aecona Pty Ltd, was wound down and subsequently deregistered.

**2.9 Comparatives**

Certain comparative figures in the statement of profit or loss and other comprehensive income have been reclassified for consistency with current year presentation.

**Change in presentation of the statement of profit or loss and other comprehensive income**

Following a review of the Company’s financial statements, the Company has elected to adjust the presentation of its statement of profit or loss and other comprehensive income for the current reporting period and the comparative period, on the basis that the revised presentation by function of expense is considered more relevant to the users of the financial statements, and no less reliable.

The line items from statement of profit or loss and accompanying notes as previously reported and as reclassified to conform to the current period presentation are as follows:

Item	Previously reported Year ended 31 December 2024 \$	Reclassifications \$	Currently reported Year ended 31 December 2024 \$
<b>Revenue and other income</b>			
Other Income	7,059,075	200,417	7,259,492
<b>Expenses</b>			
Community Initiatives	(7,923,270)	(159,737)	(8,083,007)
Corporate Services	(6,511,414)	737,526	(5,773,888)
Medical and Scientific Research	(10,037,782)	1,533,586	(8,504,196)
Clinical Expenses	(17,826,298)	(2,311,792)	(20,138,090)

There was no change in the reported comprehensive loss for 2024 as a result of the reclassifications.

**Notes to the consolidated financial statements**  
**For the year ended 31 December 2025**

**3 Significant accounting judgements, estimates and assumptions**

The preparation of consolidated financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of assets and liabilities, and the accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.

**Estimates and assumptions**

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, which have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. The Group based its assumptions and estimates on parameters available when the financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Group. Such changes are reflected in the assumptions when they occur.

**Provision for expected credit losses (“ECLs”)**

The Group uses a provision matrix to calculate ECLs for trade and other receivables and cash balances. The assessment of the correlation between historical observed default rates, forecast economic conditions and ECLs is a significant estimate. The amount of ECLs is sensitive to changes in circumstances and of forecast economic conditions. The Group’s historical credit loss experience and forecast of economic conditions may also not be representative of the customer’s actual default in the future. The information about the ECLs on the Group’s trade and other receivables is disclosed in Note 11.

**Revenue from contracts with customers**

Key judgements include determining whether the contract is enforceable, whether the performance obligations are sufficiently specific, the timing of revenue from contracts with customers in terms of timing of satisfaction of performance obligations and determining the transaction price and the amounts allocated to performance obligations. The information about the revenue from contracts with customers is disclosed in Note 4.

**Income for not-for-profit entities**

Key judgements include determining whether funds are restricted and whether there is an obligation to repay unspent funds. The information about other income is disclosed in Note 5.

**Impairment of non-financial assets**

The Group determines whether non-financial assets are impaired at least on an annual basis. If an indicator of impairment exists, then this requires an estimate of the recoverable amount of the asset or cash-generating unit to which the non-current asset is allocated to be determined. The Group’s accounting policy with regards to impairment of non-financial assets is discussed in Note 15.

**Annual leave**

Liabilities for annual leave expected to be settled within twelve months of the reporting date are recognised in provisions in respect of employees’ services up to the reporting date. They are measured at the amounts expected to be paid when the liabilities are settled. Non-accumulating sick leave is recognised when the leave is taken and measured at the rates paid or payable.

**Long service leave**

A liability for long service leave is recognised, and is measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using the maturity rates of corporate bonds and inflated using a long-term inflation rate.

**Lions Eye Institute Limited**  
**ACN 106 521 439**

**Notes to the consolidated financial statements**  
**For the year ended 31 December 2025**

**4 Revenue from ordinary activities**

	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
Sale of goods and services revenue	23,792,918	22,026,442
Grant funding	11,783,720	13,032,697
Donations and bequests	2,090,949	2,046,009
Other ancillary income	2,904,846	2,760,223
	<u>40,572,433</u>	<u>39,865,371</u>
Point in time recognition	28,788,713	26,832,674
Over time recognition	11,783,720	13,032,697
	<u>40,572,433</u>	<u>39,865,371</u>

All revenue is derived in Australia.

**Revenue recognition policy**

The Group recognises revenue under AASB 15 *Revenue from contracts with customers* ("AASB 15") or AASB 1058 *Income for not-for-profit entities* ("AASB 1058"), where appropriate. In cases where there is an enforceable contract with a customer with sufficiently specific performance obligations, the transaction is accounted under AASB 15 where income is recognised when the performance obligations are satisfied. Revenue is measured based on the consideration to which the Group expects to be entitled in a contract with a customer and excludes amounts collected on behalf of third parties.

AASB 1058 applies when a not-for-profit entity enters into a transaction where the consideration paid to acquire an asset is significantly less than the fair value of the asset acquired principally to enable the Group to further its objectives. Any excess over the carrying amount of the asset acquired is recognised in the profit or loss as income. Income is recognised when the Group obtains control of the asset.

**Revenue from sale of goods and services, clinical income and other ancillary income**

Revenue from sale of goods and services, clinical income, and other ancillary income is recognised at the point in time when either control of the good sold is transferred to the customer or the service is rendered. This is reflective of the transfer of control of the good or service to the customer.

**Grants (including research)**

The Group receives various grants for purposes of funding specific research and other activities. Revenue is measured at the amount of consideration to which the Group expects to be entitled to in exchange for the provision of the various milestones. Revenue is recognised over time as the services are provided with reference to the input method over the period during which the milestones are achieved.

When there are conditions attached to funds received for specific purposes then these funds are recognised in the consolidated statement of financial position as a contract liability until such conditions are met or the services provided.

The Group also receives grants to be used for its principal activities with no restrictions. As there are no sufficiently specific performance obligation under these arrangements, grant revenue is recognised at the point in time when the amount is received by the Group or when the Group becomes entitled to the amount.

For capital grants such as grants received to acquire or construct an asset, income is recognised when or as the obligations of the capital grants are met which will be when the asset is acquired or over the construction period.

**Donations and bequests**

The Group receives donations or bequests with no restrictions to enable the Group to further its objectives. Donation or bequest income is measured at the fair value of the consideration or asset received. Donation or bequest income is recognised at the point in time when the Group obtains control over the asset.

**Lions Eye Institute Limited**  
**ACN 106 521 439**

**Notes to the consolidated financial statements**  
**For the year ended 31 December 2025**

**4 Revenue from ordinary activities (continued)**

**Contract liabilities**

A contract liability is recognised if a payment is received, or a payment is due (whichever is earlier) from a customer before the Group transfers the related goods or services. Contract liabilities are recognised as revenue when the Group performs under the relevant contract (i.e., transfers control of the related goods or services to the customer).

**5 Other income**

	<b>2025</b>	<b>2024</b>
	\$	\$
Prizes	-	5,070,828
Interest income	431,030	258,167
Dividend income	1,631,923	1,552,442
Realised foreign exchange gain	-	17,405
Net gain on sale of financial assets	-	360,650
	<u>2,062,953</u>	<u>7,259,492</u>

**Dividend income**

Dividend income is earned from the investments in equity funds and shares, which are classified as financial assets at fair value through profit or loss. Dividend income is recognised when the Group has established that it has a right to receive a dividend.

**Interest income**

Interest income is recognised as interest accrues using the effective interest rate ("EIR") method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the EIR.

**Prizes**

Prizes are recognised when the funds are received or become unconditionally receivable by LEI. Prizes are distinct from grants, which are provided by the grantor for the purpose of future expenditure, whilst prizes represent unconditional amounts received or receivable by LEI.

**Net gain on sale of financial assets**

The gain on the sale of financial assets is recognised when the assets are sold for more than their carrying value. The gain or loss is determined by the difference between the recorded value and the actual proceeds from the sale of the financial assets.

**6 Community initiatives**

	<b>2025</b>	<b>2024</b>
	\$	\$
Consumable and other expenses	1,521,247	1,232,835
Depreciation	350,964	285,135
Employment expenses	4,791,972	5,756,783
Lions Outback Vision travel expenses	698,833	808,254
Office and administration expenses	1,782	-
	<u>7,364,798</u>	<u>8,083,007</u>

**Lions Eye Institute Limited**  
**ACN 106 521 439**

**Notes to the consolidated financial statements**  
**For the year ended 31 December 2025**

**7 Corporate services**

	<b>2025</b>	<b>2024</b>
	\$	\$
Depreciation	794,937	824,766
Employment expenses	2,589,941	2,871,181
Fundraising expenses	282,910	279,119
Office and administration expenses	1,099,715	629,776
Infrastructure and maintenance expenses	1,265,329	1,151,994
Interest on corporate loan	21,500	-
Net loss on sale of assets	48,014	17,052-
	<u>6,102,346</u>	<u>5,773,888</u>

**8 Medical and scientific research**

	<b>2025</b>	<b>2024</b>
	\$	\$
Depreciation	633,389	376,518
Employment expenses	4,747,705	4,098,909
Research expenses	3,271,678	4,028,769
	<u>8,652,772</u>	<u>8,504,196</u>

**9 Clinical expenses**

	<b>2025</b>	<b>2024</b>
	\$	\$
Consumables and other expenses	7,407,200	6,612,911
Depreciation	1,106,589	1,174,643
Employment expenses	12,596,706	12,331,383
Net loss on sale of assets	-	19,153
	<u>21,110,495</u>	<u>20,138,090</u>

**10 Cash and cash equivalents**

	<b>2025</b>	<b>2024</b>
	\$	\$
Cash at bank and on hand	6,852,542	11,637,497
Total cash at bank, on hand and deposits	<u>6,852,542</u>	<u>11,637,497</u>
Restricted cash	1,538	1,478
Total restricted cash	<u>1,538</u>	<u>1,478</u>
Total cash and cash equivalents	<u>6,854,080</u>	<u>11,638,975</u>

The general cash available is as follows:

Short term cash at bank and at call deposits	6,854,080	11,638,975
--	-----------	------------

**Lions Eye Institute Limited**  
**ACN 106 521 439**

**Notes to the consolidated financial statements**  
**For the year ended 31 December 2025**

**10 Cash and cash equivalents (continued)**

Research grant and other funds held on behalf of others	(1,538)	(1,478)
General cash available	6,852,542	11,637,497
	<u>6,852,542</u>	<u>11,637,497</u>

Cash and cash equivalents in the consolidated statement of financial position comprises cash at banks and on hand and short-term deposits with maturity of three months or less, that are readily convertible to a known amount of cash and subject to an insignificant risk of changes in value.

Cash at bank earns interest at floating rates based on daily bank deposit rates. Short-term deposits are made for varying periods of between one day and three months, depending on the immediate cash requirements of the Group, and earn interest at the respective short-term deposit rates. The carrying amounts of cash and cash equivalents approximate their fair value.

Restricted cash represents funds earmarked for specific purposes that are spent at the discretion of the Group.

**Research grant and other funds held on behalf of others**

Research grant and other funds held on behalf of others represent funds received for research purposes and on behalf of researchers with the Group as the research institution.

**11 Trade and other receivables**

	2025	2024
	\$	\$
Trade and other receivables	4,011,061	4,644,729
Provision for expected credit losses	(27,071)	(61,582)
	<u>3,983,990</u>	<u>4,583,147</u>

Trade and other receivables are non-interest bearing and are generally on terms of 30 to 90 days.

**Recognition and measurement**

Trade and other receivables are initially recognised at the fair value of the consideration receivable including directly attributable transaction costs. Trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient are measured at the original transaction price.

**Subsequent measurement**

Considering that trade and other receivables are settled within the short term, the Group does not consider the effect of time value of money to be material. Trade and other receivables are therefore subsequently measured at cost and considered for impairment in line with the ECL model as described below.

**Impairment**

The Group recognises an allowance for ECL for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original EIR. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

For trade and other receivables, the Group applies a simplified approach in calculating ECLs. Therefore, the Group does not track changes in credit risk, but instead recognises a loss allowance based on lifetime ECLs at each reporting date. The Group has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.

**Lions Eye Institute Limited**  
**ACN 106 521 439**

**Notes to the consolidated financial statements**  
**For the year ended 31 December 2025**

**12 Other current assets**

	<b>2025</b>	<b>2024</b>
	\$	\$
Prepayments	740,817	508,555

Prepayments include prepaid insurance and other prepayments.

**13 Financial assets at fair value through profit or loss**

	<b>2025</b>	<b>2024</b>
	\$	\$
Financial assets at fair value through profit or loss*	37,881,289	37,702,513

Fair values of these investments are determined by reference to the most recent available published prices of the respective funds.

Financial assets at fair value through profit or loss are carried in the consolidated statement of financial position at fair value with net changes in fair value recognised in the statement of profit or loss.

This category includes listed equity investments which the Group had not elected to classify at fair value through other comprehensive income. Dividends on listed equity investments are recognised as other income in the consolidated statement of profit or loss when the right of payment has been established.

\* Includes restricted balances as follows:

	<b>2025</b>	<b>2024</b>
	\$	\$
Ian Constable Chair Fund	9,570,685	9,392,814
Joyce Henderson Bequest	2,860,723	2,810,650
Research grant held on behalf of others	1,249,961	966,438
Total – restricted balances	13,681,369	13,169,902

**Restricted investment – Ian Constable Chair in Discovery and Translational Ophthalmic Science**

Donations received in response to a fundraising campaign to endow the Ian Constable Chair in Discovery and Translational Ophthalmic Science at the University of Western Australia have been designated by the Group as restricted use and the balance invested in investments in equity funds and shares as approved by the Finance, Audit and Investment Committee.

**Restricted investment – Joyce Henderson bequest**

The Group manages the Joyce Henderson Bequest Fund for Children's Eye Research, which was established in December 2011. The fund is used to fund in perpetuity a Paediatric Ophthalmology Fellowship position. This has been designated by the Group as restricted use and the balance invested in investments in equity funds and shares as approved by the Finance, Audit and Investment Committee.

**Research grant held on behalf of others**

Research grant held on behalf of others represent funds received for research purposes and on behalf of researchers with the Group as the research institution.

# Lions Eye Institute Limited

## ACN 106 521 439

### Notes to the consolidated financial statements

#### For the year ended 31 December 2025

#### 14 Investment in an associate

The Company owns 39.9% (2024: Nil) interest in an associate called Ninnox Vision Pty Ltd. During the year, the Company made an initial investment of \$1,000,000 in the associate. The Company's share in the loss of the associate amounted to \$79,762 during the year ended 31 December 2025 (2024: \$Nil) .

#### Recognition and measurement

An associate is an entity over which the Group has significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the investee, but is not control or joint control over those policies. The considerations made in determining significant influence are similar to those necessary to determine control over subsidiaries.

The Group's investment in its associate is accounted for using the equity method. Under the equity method, the investment in an associate is initially recognised at cost. The carrying amount of the investment is adjusted to recognise changes in the Group's share of net assets of the associate since the acquisition date. The aggregate of the Group's share of profit or loss of the associate is shown on the face of the consolidated statement of profit or loss and represents profit or loss after tax of the associate.

After application of the equity method, the Group determines whether it is necessary to recognise an impairment loss on its investment in its associate. At each reporting date, the Group determines whether there is objective evidence that the investment in the associate is impaired. If there is such evidence, the Group calculates the amount of impairment as the difference between the recoverable amount of the associate and its carrying value, and then recognises the loss in the consolidated statement of profit or loss. Impairments (and reversals of impairment) are presented within 'Share of profit/loss of an associate' in the consolidated statement of profit or loss. The consolidated statement of profit or loss reflects the Group's share of the results of operations of the associate.

**Lions Eye Institute Limited**  
**ACN 106 521 439**

**Notes to the consolidated financial statements**  
**For the year ended 31 December 2025**

**15 Property, plant and equipment**

Movements in the carrying amounts for each class of property, plant and equipment between the beginning and the end of the current financial year were as follows:

	Land	Buildings	Leasehold Improvements	Building improvements	Plant, equipment & motor vehicles	Capital works in progress	Total
	\$	\$	\$	\$	\$	\$	\$
<b>Cost</b>							
At 1 January 2025	1,350,000	12,966,957	778,615	5,803,211	20,476,070	1,176,942	42,551,795
Additions	-	-	11,445	183,209	1,228,130	7,989,565	9,412,349
Disposals	-	-	-	-	(45,000)	-	(45,000)
Transfers	-	-	-	-	-	(1,422,784)	(1,422,784)
<b>At 31 December 2025</b>	<b>1,350,000</b>	<b>12,966,957</b>	<b>790,060</b>	<b>5,986,420</b>	<b>21,659,200</b>	<b>7,743,723</b>	<b>50,496,360</b>
<b>Depreciation</b>							
At 1 January 2025	-	5,025,215	78,051	2,735,305	15,313,358	-	23,151,929
Depreciation	-	259,340	38,978	288,372	1,743,620	-	2,330,310
Disposals	-	-	-	-	(45,000)	-	(45,000)
<b>At 31 December 2025</b>	<b>-</b>	<b>5,284,555</b>	<b>117,029</b>	<b>3,023,677</b>	<b>17,011,978</b>	<b>-</b>	<b>25,437,239</b>
<b>Carrying amounts</b>							
<b>At 31 December 2025</b>	<b>1,350,000</b>	<b>7,682,402</b>	<b>673,031</b>	<b>2,962,743</b>	<b>4,647,222</b>	<b>7,743,723</b>	<b>25,059,121</b>
At 31 December 2024	1,350,000	7,941,742	700,564	3,067,906	5,162,712	1,176,942	19,399,866

**Recognition and measurement**

Property, plant and equipment is initially recognised at acquisition cost, including any costs directly attributable to bringing the asset into the location and condition necessary for it to be capable of operating in the manner intended by the management. Property, plant and equipment that has been contributed at no cost, or for nominal cost, is valued and recognised at the fair value of the asset at the acquisition date. Capital work in progress is stated at cost, net of accumulated impairment losses, if any. Depreciation of the asset begins when construction is complete and the asset is available for use.

**Subsequent measurement**

Property, plant and equipment is subsequently measured using the cost model, less accumulated depreciation and impairment losses.

**Depreciation**

Depreciation is calculated on a straight-line basis over the useful lives of the assets, commencing from the time the asset is held ready for use. Land is not depreciated.

**Lions Eye Institute Limited**  
**ACN 106 521 439**

**Notes to the consolidated financial statements**  
**For the year ended 31 December 2025**

**15 Property, plant and equipment (continued)**

The useful lives of the assets are determined on an individual basis but in general the annual depreciation rates used for each class of depreciable assets are:

	<b>2025</b>	<b>2024</b>
	%	%
<b>Class of property, plant and equipment</b>		
Buildings	2 - 4	2 – 4
Building improvements	5 - 20	5 – 20
Plant and equipment (including motor vehicles)	5 - 25	5 – 25

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at each reporting date.

**Impairment**

The Group assesses at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Group estimates the asset's recoverable amount. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

The recoverable amount is the higher of an asset's fair value less costs of disposal and its value in use. Fair value less costs of disposal is the price obtainable from selling the asset, minus disposal costs. Value in use is the present value of expected future cash flows from the asset.

**Derecognition**

Any gain or loss on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the consolidated statement of profit or loss when the asset is derecognised.

**16 Leases**

**Right-of-use assets**

	<b>2025</b>	<b>2024</b>
	\$	\$
Right-of-use assets – at cost	3,746,269	3,928,886
Accumulated depreciation	(2,900,393)	(2,344,825)
	845,876	1,584,061
At 1 January	1,584,061	1,180,585
Additions	-	913,351
Modifications/lease remeasurement	(182,616)	-
Depreciation	(555,569)	(509,875)
<b>At 31 December</b>	<b>845,876</b>	<b>1,584,061</b>

**Lions Eye Institute Limited**  
**ACN 106 521 439**

**Notes to the consolidated financial statements**  
**For the year ended 31 December 2025**

**16 Leases (continued)**

**Lease liabilities**

	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
At 1 January	1,766,417	1,422,360
Additions	-	913,351
Modifications	(182,615)	-
Payments	(702,237)	(680,356)
Accretion of interest	80,277	111,061
<b>At 31 December</b>	<b>961,842</b>	<b>1,766,416</b>
Lease liability – non-current	605,056	591,668
Lease liability – current	356,786	1,174,748

The Group assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

**The Group as a lessee**

The Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Group recognises lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

**Measurement and recognition of leases as a lessee**

At lease commencement date, the Group recognises a right-of-use asset and a lease liability on the consolidated statement of financial position. The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the Group, an estimate of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made in advance of the lease commencement date (net of any incentives received). Where the Group has a number of leases that have significantly below-market terms and conditions then these are also recognised at cost.

The Group depreciates the right-of-use assets on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. Depreciation expense has been included in Clinical & corporate services expenses. The Group also assesses the right-of-use asset for impairment when impairment indicators exist.

The Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the interest rate implicit in the lease if that rate is readily available or the incremental borrowing rate where the rate implicit in the lease is not readily determinable. Lease payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments based on an index or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably certain to be exercised.

Subsequent to initial measurement, the liability will be reduced for payments made and increased for interest. It is remeasured to reflect any reassessment or modification, or if there are changes in in-substance fixed payments. When the lease liability is remeasured, the corresponding adjustment is reflected in the right-of-use asset or profit and loss if the right-of-use asset is already reduced to zero.

# Lions Eye Institute Limited

## ACN 106 521 439

### Notes to the consolidated financial statements

#### For the year ended 31 December 2025

#### 16 Leases (continued)

The Group has elected to account for short-term leases and leases of low-value assets using the practical expedients. Instead of recognising a right-of-use asset and lease liability, the payments in relation to these are recognised as an expense in the statement of profit or loss on a straight-line basis over the lease term.

The Group's leases are both commercial leases and peppercorn leases, but the values above do not contain any component of the peppercorn leases. Management has opted to use the cost approach for the accounting treatment of both peppercorn leases of which the values were \$0 and \$1 and therefore any values of those leases are not recognised in the consolidated financial statements. The peppercorn leases relate to facilities used for medical and scientific research to achieve the Group's principal activities. These leases are automatically renewed upon termination, unless terminated by the lessors.

Presented below is a maturity analysis of future lease payments:

	<b>2025</b>	<b>2024</b>
	\$	\$
Within 1 year	417,157	701,966
Later than 1 year but not more than 5 years	698,744	1,337,884
	<u>1,115,901</u>	<u>2,039,850</u>

The amount of expense relating to short-term leases and leases of low-value assets recognised in profit or loss for the year ended 31 December 2025 is \$900 (2024: \$900).

#### 17 Trade and other payables

	<b>2025</b>	<b>2024</b>
	\$	\$
Trade creditors and accruals	4,733,005	4,984,364
Deferred income	2,519,925	1,526,495
Unspent research grant funds	1,249,961	2,788,029
	<u>8,502,891</u>	<u>9,298,888</u>

#### Recognition and measurement

Trade and other payables are initially measured at fair value including transaction costs.

#### Subsequent measurement

After initial measurement, trade and other payables are subsequently measured at amortised cost using the EIR method.

#### Terms and conditions

Trade payables are non-interest bearing and are normally settled on 60-day terms.

Deferred income represents unspent grant funds for unfulfilled performance obligations.

Unspent research grant funds represent funds received for research purposes and on behalf of researchers with the Group as the research institution.

**Lions Eye Institute Limited**  
**ACN 106 521 439**

**Notes to the consolidated financial statements**  
**For the year ended 31 December 2025**

**18 Employee benefit provisions**

	<b>2025</b>	<b>2024</b>
	\$	\$
<b>Current</b>		
Annual leave	1,722,728	1,768,606
Long service leave - current	1,220,803	1,285,406
	<u>2,943,531</u>	<u>3,054,012</u>
<b>Non-current</b>		
Long service leave – non-current	1,053,310	827,708
	<u>1,053,310</u>	<u>827,708</u>
<b>Aggregate employee benefits</b>	<u>3,996,841</u>	<u>3,881,720</u>

Provision for employee benefits arising from services rendered by employees have been measured at the amounts expected to be paid when the liability is settled, plus related on-costs. Other employee benefits payable later than one year have been measured at the present value of the estimated future cash outflows to be made for those benefits.

**19 Borrowings and borrowing costs**

	<b>2025</b>	<b>2024</b>
	\$	\$
<b>Borrowings - non-current</b>		
Corporate loan	2,007,184	-
	<u>2,007,184</u>	<u>-</u>

During the year, the Company entered into a \$5 million corporate loan facility to provide funding for redevelopment of the Company's day surgery unit. An initial draw down of \$2 million was made on 8 December 2025. The loan has an interest rate of 4.7411% with the loan initially being interest only for a two year period prior to repayments of \$150,000 per quarter commencing on 31 December 2027. The outstanding balance is repayable in full on 8 December 2028 or renegotiate with the bank for a maximum of 10 years.

The loan is secured by a security interest and charge over all of the present and future rights, property and undertakings of the Company.

An additional \$3 million was drawn down subsequent to year end. This drawdown has been disclosed as a subsequent event in note 24.

**Recognition and measurement**

Borrowings are initially measured at fair value less transaction costs incurred.

**Subsequent measurement**

After initial measurement, borrowings are subsequently measured at amortised cost using the EIR method.

**Borrowing costs**

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalised as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.

# Lions Eye Institute Limited

## ACN 106 521 439

### Notes to the consolidated financial statements

#### For the year ended 31 December 2025

#### 20 Commitments and contingencies

##### Capital commitments

Capital commitments in relation to contracts for property, plant and equipment at the reporting date but not recognised as liabilities amount to \$9,700,000 (2024: \$13,200,000)

Redevelopment works to increase the capacity of the Lions Eye Institute Day Surgery Centre to two theatres commenced during the financial year. As at 31 December 2025 expenditure of \$6,300,000 had been incurred and capitalised as work in progress. The redevelopment is expected to be completed in early 2027.

##### Contingencies

At December 2025, the Group has no contingencies (2024: Nil).

The Group occasionally receives claims which arise in the normal course of business. Where the Group is in receipt of such claims it reviews their nature and substance in order to assess the need for accounting recognition or disclosure. The directors are of the opinion that, based on information available, there is currently no material exposure to the Group arising from actual or pending claims at balance date.

#### 21 Member's guarantee

The Company is incorporated under the *Corporations Act 2001* and is a public company limited by guarantee. If the Company is wound up, the constitution states that each member is required to contribute a maximum of \$10 each towards meeting any outstanding and obligations of the Company. At 31 December 2025, the number of members is 50 (2024: 49).

#### 22 Related party disclosure

	2025	2024
	\$	\$
Compensation of key management personnel		
Compensation expense of key management personnel	1,965,387	1,412,140

#### 23 Auditor's remuneration

The Company's auditor is Ernst & Young Australia.	2025	2024
	\$	\$
Audit services	99,000	96,600
Other services	14,450	14,100
	113,450	110,700

#### 24 Subsequent events

Subsequent to year end, an additional \$3 million of the corporate loan facility disclosed in Note 19 of the Financial Statement was drawn down on 3 February 2026.

On 15 January 2026, the Company made an additional investment of \$4,000,000 in Ninnox.

**Lions Eye Institute Limited**  
**ACN 106 521 439**

**Notes to the consolidated financial statements**  
**For the year ended 31 December 2025**

**24 Subsequent events (continued)**

No other matters or circumstances that have arisen since the end of the financial year that have significantly affected or may significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in future years.

No other matters or circumstances that have arisen since the end of the financial year that have significantly affected or may significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in future years.

**Lions Eye Institute Limited**

**ACN 106 521 439**


**Directors' declaration**

**31 December 2025**

In accordance with a resolution of the Directors of Lions Eye Institute Limited ("the Company"), we state that in the opinion of the Directors:

- (a) the consolidated financial statements and notes of the Group are in accordance with the *Australian Charities and Not-For-Profits Commission Act 2012*, including:
  - (i) giving a true and fair view of the Group's financial position as at 31 December 2025 and its performance for the year ended on that date; and
  - (ii) complying with Australian Accounting Standards – Simplified Disclosures and the *Australian Charities and Not-for-Profits Commission Regulations 2022*; and
  
- (b) there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

Signed in accordance with the resolution of the Board of Directors:



.....

Anthony Joyner  
Chair



.....

Glen Power  
Managing Director

Signed at Perth this 15 day of May 2026

# Lions Eye Institute Limited and its controlled entities

## ACN 106 521 439

### Independent auditor's report



Ernst & Young  
9 The Esplanade  
Perth WA 6000 Australia  
GPO Box M939 Perth WA 6843

Tel: +61 8 9429 2222  
Fax: +61 8 9429 2436  
ey.com/au

## Independent auditor's report to the members of Lions Eye Institute Limited

### Opinion

We have audited the financial report of Lions Eye Institute Limited (the Company) and its subsidiaries (collectively the Group), which comprises the consolidated statement of financial position as at 31 December 2025, the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended, notes to the consolidated financial statements, including material accounting policy information, and the directors' declaration.

In our opinion, the accompanying financial report of the Group is in accordance with the *Australian Charities and Not-for-profits Commission Act 2012* and the *Associations Incorporation Act 2015*, including:

- a. Giving a true and fair view of the consolidated financial position of the Group as at 31 December 2025 and of its consolidated financial performance for the year ended on that date; and
- b. Complying with Australian Accounting Standards - Simplified Disclosures and the *Australian Charities and Not-for-profits Commission Regulations 2022*.

### Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial report* section of our report. We are independent of the Group in accordance with the ethical requirements of the Accounting Professional and Ethical Standards Board's *APES 110 Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Information other than the financial report and auditor's report thereon

The directors are responsible for the other information. The other information is the directors' report accompanying the financial report.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.



### **Responsibilities of the directors for the financial report**

The directors of the Company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards - Simplified Disclosures, the *Australian Charities and Not-for-profits Commission Act 2012* and the *Associations Incorporation Act 2015* and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters relating to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

### **Auditor's responsibilities for the audit of the financial report**

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.

# Lions Eye Institute Limited and its controlled entities

## ACN 106 521 439

### Independent auditor's report



Page 3

- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.
- Plan and perform the Group audit to obtain sufficient appropriate audit evidence regarding the financial information of the entities or business units within the Group as a basis for forming an opinion on the Group financial report. We are responsible for the direction, supervision and review of the audit work performed for the purposes of the Group audit. We remain solely responsible for our audit opinion.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

A handwritten signature in black ink, appearing to read 'Ernst &amp; Young', written in a cursive style.

Ernst & Young

A handwritten signature in black ink, appearing to read 'Pierre Dreyer', written in a cursive style.

Pierre Dreyer  
Partner  
Perth  
15 May 2026

**Lions Eye Institute Limited and its controlled entities**  
**ACN 106 521 439**

**Auditor's independence declaration**



Ernst & Young  
9 The Esplanade  
Perth WA 6000 Australia  
GPO Box M939 Perth WA 6843

Tel: +61 8 9429 2222  
Fax: +61 8 9429 2438  
ey.com/au

**Auditor's independence declaration to the directors of Lions Eye Institute Limited**

In relation to our audit of the financial report of Lions Eye Institute Limited for the financial year ended 31 December 2025, and in accordance with the requirements of Subdivision 60-C of the *Australian Charities and Not-for-profits Commission Act 2012*, to the best of my knowledge and belief, there have been:

- a. No contraventions of the auditor independence requirements of any applicable code of professional conduct; and
- b. No non-audit services provided that contravene any applicable code of professional conduct.

This declaration is in respect of Lions Eye Institute Limited and the entities it controlled during the financial year.

A stylized, handwritten-style logo of the letters 'EY' in black.

Ernst & Young

A handwritten signature in black ink, appearing to read 'P. Dreyer'.

Pierre Dreyer  
Partner  
15 May 2026